RESEARCH TRIANGLE PARK, N.C. and ROTHERHAM, United Kingdom, Jan. 12, 2016 /PRNewswire/ -- Triangle Research Labs, LLC (TRL) and Kirkstall, Ltd, are pleased to announce TRL as the primary distributor of Kirkstall’s 3-D cell fluidic culture system, QuasiVivo®, in the US and Canada.
“We were searching for an organization to provide specialist market knowledge and help us deliver outstanding support to our US customers,” said Dr. Malcolm Wilkinson, CEO of Kirkstall. “TRL has a great reputation and already supply cell culture technology that is complementary to the QuasiVivo® System.”
Historically, in vitro biomedical research has relied on cell culture models developed using 6- 24- and 96- well plates, but these provide a basic model of physiological conditions in-vivo. 3-D cell culture is one of the fastest growing segments of the cell culture tools market for drug development, toxicity testing, cancer research, and stem cell regenerative medicine research.
Kirkstall’s QuasiVivo® technology enables creation of cell culture models that are more predictive of what is likely to happen in the clinic, which could lead to improved patient safety and reduction of attrition in later stages of drug development.
“Researchers in cell biology are now recognizing the need for complex cell culture model systems to provide more relevant predictive value. Improvements in hepatocytes physiology and function are apparent when cells are cultured in low-shear-stress fluidics such as provided in the QuasiVivo® system,” said Maureen Bunger, PhD and Technical Director at TRL. “The QuasiVivo is a highly versatile system that supports hepatocytes function for more than three weeks enabling researchers to perform longer-term experiments using primary hepatocytes than they can in a typical static culture system. It’s a great complement to TRL’s current product line.”
Visit www.triangleresearchlabs.net/products-hepatocytes/quasivivo to learn more about QuasiVivo® products.
About Kirkstall Ltd
Kirkstall Ltd was founded in UK in 2007 to commercialize the research results from a leading biomedical team at the University of Pisa, Italy. Its headquarters are in Rotherham, UK at the center of a cluster of leading biomedical research organizations.
The Quasi Vivo® system provides a constant, controllable flow of media across the cell culture. This flow provides a consistent supply of nutrients and oxygen to the cells, as well as removing waste, allowing 2D and 3D cultures to be maintained for more than 28 days. The modular nature of the system allows for multiple chambers to be connected, allowing for the modelling of more complex cellular interactions.
About TRL, LLC
Triangle Research Labs, LLC (TRL) launched in Research Triangle Park, North Carolina in 2011. TRL provides high-quality primary human and animal hepatocytes for use in pre-clinical ADMETox applications. The biotechnology company distributes cryopreserved NoSpin HepaRG cells and related media for Biopredic International and recently began distributing QuasiVivo® Cell Culture Flow Systems for Kirkstall Ltd. TRL’s expert staff has decades of experience in the hepatic sciences and a strong commitment to providing high quality products that consistently exceed customer expectations. Known for developing lasting relationships, TRL strives to understand individual research needs, and work mutually towards the common goal of improving the quality of life.
Logo - http://photos.prnewswire.com/prnh/20150915/266778LOGO
Logo - http://photos.prnewswire.com/prnh/20160112/321345LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/triangle-research-labs-to-distribute-quasivivo-products-in-the-us-and-canada-300203095.html
SOURCE TRL
